Is it time to implement adjuvant targeted therapy in EGFR-mutant non-small-cell lung cancer?

Amit A. Kulkarni; Abdul Rafeh Naqash; Sonam Puri; Rodrigo Dienstmann

doi:10.1200/PO.20.00460

Is it time to implement adjuvant targeted therapy in EGFR-mutant non-small-cell lung cancer?

Amit A. Kulkarni, Abdul Rafeh Naqash, Sonam Puri, Rodrigo Dienstmann

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Original language	English (US)
Pages (from-to)	408-414
Number of pages	7
Journal	JCO Precision Oncology
Volume	5
DOIs	https://doi.org/10.1200/PO.20.00460
State	Published - 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1200/PO.20.00460

OpenUrl availability

Full text

Cite this

@article{bdafd46977fa44218a4d21e2a64dac1c,

title = "Is it time to implement adjuvant targeted therapy in EGFR-mutant non-small-cell lung cancer?",

author = "Kulkarni, {Amit A.} and Naqash, {Abdul Rafeh} and Sonam Puri and Rodrigo Dienstmann",

year = "2021",

doi = "10.1200/PO.20.00460",

language = "English (US)",

volume = "5",

pages = "408--414",

journal = "JCO Precision Oncology",